Naturlose(R) Dosage Test Shows Positive Effect

Spherix Incorporated
(Nasdaq: SPEX) has successfully completed its dose range-finding study,
allowing it to continue with its Phase 3 clinical trial of Naturlose as a
treatment for type 2 diabetes (see Spherix news releases dated May 23,
2006, and August 10, 2006). The tests were done on human subjects to
establish the appropriate dosage and timing to be used in the upcoming
trial. The Company will now recruit patients for the trial, which will take
place in Australia and the United States. Company officials expect that the
first participants will begin the Phase 3 clinical trial by April 2007.



"The test results so far have been positive," said Spherix President
Richard Levin. "Not only did they determine the dose and timing for the
trial, but the results corroborate what we have seen in smaller, previous
tests -- that Naturlose has a beneficial effect on modulating postprandial
blood glucose, an important factor in the treatment of Type 2 diabetes. We
are moving forward with confidence that we have a scientifically sound
foundation on which to complete the Phase 3 trial, and to anticipate a
favorable outcome."



Levin said that the Company's recently announced settlement of a
contract dispute (see Spherix's PR released earlier today) in its
reservations business will bolster its financial ability to support
Naturlose. In that settlement, Spherix agreed to accept $6 million to end
the longstanding legal dispute over the award of the National Recreation
Reservation Service contract. Spherix intends to use a portion of that
payment to support its efforts to develop Naturlose as a marketable
product. Spherix believes these funds, along with existing cash, will
ensure its ability to complete the Phase 3 clinical trial.



If the Phase 3 trial establishes that Naturlose is an effective
treatment for diabetes, Spherix will prepare a New Drug Application (NDA)
for presentation to the Food and Drug Administration (FDA). FDA approval
would give Spherix the right to market Naturlose as a diabetes drug.
Naturlose has already been shown to be safe.



Certain statements contained herein are "forward looking" statements as
defined in the Private Securities Litigation Reform Act of 1995. Because
such statements include risks and uncertainties, actual results may differ
materially from those expressed or implied. Factors that could cause actual
results to differ materially from those expressed or implied include, but
are not limited to, those discussed in filings by the Company with the
Securities and Exchange Commission, including the filing on Form 8-K made
on March 3, 1999.


Under its motto, "A World of Solutions," Spherix's mission is to create
value and increase shareholder wealth through innovations that benefit our
clients and the human condition. Spherix offers innovations in information
technology, knowledge management, and biotechnology.


Spherix Incorporated

spherix/

Our Recommendations:


•   Buy Emla Online
•   Order Elavil Online
•   Buy Norvasc